Get Free Demat Account*
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
By Dalal Street Investment Journal (DSIJ)
Orchid Pharma share price gained 9% after the company signed a licensing and supply agreement with Russia's Pharmasyntez JSC to commercialise Exblifep. The deal represents a potential $178 million opportunity over 10 years, subject to regulatory approval.
Orchid Pharma share price was trading at ₹1,013.30 as of 10:03 AM, 2026, up 9% for the day. The stock touched an intraday high of ₹1,047.00 and a low of ₹970.05. Trading volume stood at 12.30 lakh shares, compared with the 30-day average of 1.89 lakh shares, marking the highest single-day volume recorded since September 19, 2025, as the company disclosed a significant international licensing agreement on July 7, 2026.
Orchid Pharma Limited has entered into a licensing and supply agreement with Pharmasyntez JSC, a Russian pharmaceutical company, for the commercialisation of Exblifep (cefepime/enmetazobactam) in Russia.
Under the terms of the agreement, Pharmasyntez will hold exclusive rights to register and commercialise Exblifep in Russia, while Orchid Pharma will supply the finished dosage form. The arrangement is subject to regulatory approval by the Ministry of Health of the Russian Federation. The company has described the partnership as representing a potential opportunity of approximately $178 million over the first 10 years, showing the scale of unmet clinical need and hospital procurement volumes in the Russian market.
Exblifep is a carbapenem-sparing antibiotic, meaning it is designed to treat serious bacterial infections without relying on carbapenems, which are typically reserved for last resort. The drug is a combination of cefepime, a fourth-generation cephalosporin, and enmetazobactam, a beta-lactamase inhibitor that helps the antibiotic overcome bacterial resistance.
It is used for treating complicated urinary tract infections (cUTI) and hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP) caused by Gram-negative bacteria. This is because these infections are becoming more and more difficult to treat as a result of increasing antibiotic resistance of bacteria.
Exblifep holds approvals from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). It is included in IDSA and EUCAST treatment guidelines. According to the company, it is the first new chemical entity (NCE) originating from an Indian pharmaceutical company to receive regulatory approval in both the United States and Europe.
Manish Dhanuka, Managing Director of Orchid Pharma, said the partnership marks an important step in making Exblifep available to patients in Russia, citing Pharmasyntez's reach into Russian hospital procurement as a key reason for selecting them as a partner.
Natalia Malykh, Vice President of Business Development at Pharmasyntez, noted that antimicrobial resistance is one of the most significant challenges in modern medicine and described the agreement as enabling Russian patients to access modern antibacterial therapy.
Orchid Pharma Limited is a fully vertically integrated pharmaceutical company with capabilities spanning Key Starting Materials (KSMs), Active Pharmaceutical Ingredients (APIs), and Finished Dosage Forms (FDFs), with a focus on complex injectable antibiotics. The company operates manufacturing facilities compliant with USFDA and EU-GMP standards. It holds the distinction of being the first Indian pharmaceutical company to invent a New Chemical Entity approved in both the United States and Europe, with Exblifep now commercially marketed in both regions.
Licensing and Supply Agreement between Orchid Pharma and Pharmasyntez JSC is the beginning of the presence of Exblifep in Russia, pending regulatory approval from Russia. The agreement is valued at a potential of $178 million in the next ten years based on the substantial demand for newer antibiotics in Russian hospitals. The surge in the price of shares, with trading volume six times above its average over thirty days, is due to market reaction to the news, although the success of the commercial deal depends on the speed of regulatory approvals in Russia.
Source: Dalal Street Investment Journal (DSIJ), BSE, NSE
SEBI Registered Research Analyst (INH000006396).
Founded in 1986, Dalal Street Investment Journal (DSIJ) brings decades of experience in India’s equity markets. DSIJ's research combines fundamental analysis with price action, guided by disciplined risk management and capital preservation. They follow a structured, data-driven approach designed to help investors and traders make informed decisions beyond short-term market noise.
Disclaimer :
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited
This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading